The purpose of this survey is to provide the Canadian Cancer Survivor Network (CCSN) with insights and perspectives about the use of Opdivo (nivolumab) for the treatment of patients with Squamous Cell Carcinoma of the Head and Neck.The results of our survey are to be submitted in our patient evidence study to the pan-Canadian Oncology Drug Review (pCODR) on February 14, 2017.
To complete the survey, please click here.
